The FDA has declined to review Moderna's application for its experimental mRNA flu vaccine, citing concerns about the company's clinical trial design. The decision reverses the agency's previous approval of the same trial framework and comes amid broader federal skepticism toward mRNA vaccine technology.
The Food and Drug Administration refused to review Moderna's application for mRNA-1010, its experimental flu vaccine, according to a company announcement Tuesday. The decision affects what would be the first mRNA-based influenza vaccine, following a Phase 3 trial that enrolled nearly 41,000 participants and cost hundreds of millions of dollars.
Sources agree on the FDA's stated rationale and Moderna's response. The agency cited problems with the trial's comparator vaccines, specifically Moderna's decision to test mRNA-1010 against standard-dose flu shots like GlaxoSmithKline's Fluarix rather than high-dose vaccines for all age groups. Moderna said it was 'blindsided' by the refusal, noting the FDA had reviewed and accepted this same trial design in April 2024 and August 2025. The company's trial found mRNA-1010 superior to the comparator vaccines.
Coverage diverges on how to characterize the regulatory action itself. Some outlets present it as a technical procedural issue, while others frame it as part of a broader policy shift.
This contrast reveals different editorial judgments about regulatory consistency. The Guardian emphasizes the reversal of previous approval, while Reason highlights the disconnect between clinical evidence and regulatory inaction. Both suggest agency inconsistency, but with different implications for blame.
Multiple sources connect the decision to broader changes under Health and Human Services Secretary Robert F. Kennedy Jr., who has canceled $500 million in mRNA pandemic research funding and reduced childhood vaccine recommendations by one-third. The decision comes from Vinay Prasad, director of the Center for Biologics Evaluation and Research, who wrote that comparing mRNA-1010 to standard flu shots 'does not reflect the best-available standard of care.'
Moderna has requested a meeting with the FDA to discuss the refusal. The company noted that Fluarix has been used as a comparator in previous flu vaccine trials for products that received approval. Industry observers warn the decision could discourage future vaccine development and create uncertainty about FDA review standards for all new vaccines.
How coverage is distributed across the spectrum
Coverage spans 7 outlets with consistent policy/regulatory framing, though editorial tone varies from neutral wire reporting (Time) to more adversarial positions (Reason). One outlet (Forbes) emphasized safety/contradictions rather than regulatory procedure.